Regulatory Intelligence
We monitor, analyse, and interpret regulatory developments so they translate into clear decisions. Our regulatory intelligence is significantly shaped by the submissions we run, the scientific advice we prepare, and the lifecycle strategies we regularly execute. The same team that tracks regulatory change is the team that understands and potentially executes triggered activities.
Examples of How We Support
Below are examples to illustrate the kind of work we do day to day. The fastest way to find out more is usually via a short call: this will help us to understand your specific challenges and explore how we can help.
Precedent analysis
You are preparing for EMA scientific advice and need to understand from publicly available information how the agency has assessed comparable products. You need a precedent analysis covering approved and refused applications in the same indication, with committee opinions, conditions, and implications for your program design.
Portfolio guideline impact
Your generic portfolio spans 30 products across EU markets and you need to know which recent guideline changes affect existing authorisations. You need a structured impact assessment identifying which products require action, the regulatory pathway for each, and a prioritised timeline.
MDR landscape tracking
You are a device manufacturer planning your conformity assessment strategy and need to track MDR implementation timelines, Notified Body capacity, and MDCG guidance releases that affect your product class. You need monthly updates structured around your submission calendar.
Regulatory landscape assessment
You are conducting due diligence on a licensing target and need a regulatory landscape assessment before the data room opens. You need publicly available intelligence on the product's regulatory history, comparable approvals, and any safety-driven regulatory actions in the therapeutic class.
Understanding the Scope
Regulatory intelligence is not the same as regulatory strategy. Strategy defines the regulatory pathway and sequences the submissions. Intelligence provides the evidence base and foresight that strategy depends on: what authorities are expecting, how they have decided in comparable cases, what is changing, and what those changes mean for your product.
This page covers regulatory intelligence as a dedicated service. For the regulatory planning, submission management, and authority interactions that intelligence feeds into, see Regulatory Strategy & Operations. For safety-related intelligence and signal monitoring, see Pharmacovigilance & Device Vigilance.
What We Do
We run regulatory intelligence as both an embedded discipline (integrated into every regulatory engagement) and as a standalone, structured service with defined deliverables.
Our Workstreams
We structure our regulatory work into clear workstreams so responsibilities and handoffs are well defined.
Horizon Scanning and Surveillance
Continuous monitoring of EMA, MHRA, CMDh, FDA, and EU national authority publications. Guideline consultation tracking. Procedural and policy updates. Inspection trend analysis. Prioritised alerts filtered by client relevance.
Precedent and Comparator Research
EPAR/PAR analysis. Refusal rationale review. Committee opinion summaries. Orphan Designation outcomes assessment. Conditional and exceptional post-approval obligations. Product positioning evidence. Cross-product comparison for scientific advice preparation.
Competitor Intelligence
Marketing authorisation tracking. PIP and orphan designation monitoring. PRIME/RMAT designation tracking. Safety communication analysis. Labelling change monitoring.
Structured Deliverables
Regulatory landscape reports. Annotated regulatory trackers. Competitor precedent summaries. Product-specific intelligence briefings. Strategy input documents framing RI findings as regulatory planning recommendations.
Product-Specific Regulatory Intelligence
Therapeutic area intelligence. Guidance gap analysis for specific product classes. Risk-impact scenario modelling. Submission timing analysis based on authority decision-making patterns.
Where This Fits in the Development Journey
The nature of regulatory intelligence shifts across the lifecycle. Early phases focus on feasibility and pathway options; later phases focus on authority decision-making patterns and changes that trigger regulatory action.
Discovery & Concept
Regulatory feasibility research, pathway options analysis, classification precedent review.
Preclinical
Guideline changes affecting nonclinical requirements, authority expectations for first-in-human packages.
Design & Development
Evolving guidance relevant to CMC strategy, trial design, and endpoint selection.
Clinical
Procedural updates, competitor trial outcomes, emerging safety signals in the therapeutic area.
Regulatory Submission & Approval
Authority decision-making trends, assessment report analysis, recent refusal rationales and conditions.
Launch & Market Access
Post-approval regulatory changes, market-specific requirements, pricing and reimbursement landscape shifts.
Post-Market & Lifecycle Management
Guideline revisions triggering variations, inspection trends, safety-driven regulatory actions in the therapeutic class.
Product Type Considerations
The focus of regulatory intelligence varies by product type. These are the areas where we most frequently tailor our monitoring and analysis.
Pharmaceuticals
ICH and EMA guideline updates (quality, efficacy, safety). Variation framework changes. Impurity and nitrosamine developments. Bioequivalence and reference product precedent.
Medical Devices & IVDs
MDR/IVDR implementation updates. MDCG guidance releases. Notified Body capacity and designation changes. Common specification developments.
Combination Products
Cross-framework regulatory developments. Article 117 interpretation updates. Notified Body and competent authority coordination precedent.
Biologics & ATMPs
Evolving ATMP classification and hospital exemption interpretation. Comparability guidance. PRIME/RMAT designation outcomes. Post-approval commitment patterns.
Digital Health & SaMD
EU AI Act implementation. MDSW classification evolution. Cybersecurity guidance (MDCG and FDA). Clinical evidence expectations for AI/ML-based products.
Sample Deliverables
These are examples of what an engagement produces. The scope depends on your product, target markets, and what decisions the intelligence needs to support.
Regulatory landscape report covering regulatory pathways, authority expectations, and recent decision-making patterns for a specific indication across EU, UK, CH, and US. 
Annotated regulatory tracker: monthly summary of guideline changes, procedural updates, and inspection trends relevant to a client's product portfolio, prioritised by impact. 
Competitor precedent summary: structured analysis of approved and refused products in the same therapeutic area, with EPAR/PAR findings, committee conditions, and implications for programme design. 
Product-specific regulatory intelligence briefing: tailored analysis for a development-stage product covering relevant guidance, comparable product histories, and risk-impact scenarios for target jurisdictions. 
Strategy input document: RI findings translated into regulatory planning recommendations for a scientific advice preparation or dossier strategy review. Example Projects
Biotech Preparing for EMA Scientific Advice: Precedent Analysis for Rare Disease Programme
A biotech developing a first-in-class therapy needed to understand how EMA had assessed comparable products in the same orphan indication. We analysed EPARs, refusal rationales, and PDCO opinions for six products, identified the authority's consistent positions on endpoint selection and comparator design, and structured the findings into a briefing document that directly informed the scientific advice question set and company position.
Generics Company: Portfolio Impact Assessment Following Revised Impurity Guidelines
Following updated ICH and EMA guidance on nitrosamine risk assessment, a generics company with 40+ marketed products needed to understand which authorisations required action. We mapped the updated requirements against each product, classified the impact by urgency and variation type, and delivered a prioritised remediation timeline that the regulatory team used to plan submissions across eight EU markets.
Device Manufacturer: MDR Implementation Tracking for Conformity Assessment Planning
A Class IIb device manufacturer needed to track evolving MDR implementation timelines, Notified Body capacity, and MDCG guidance releases affecting their product class. We provided monthly structured updates aligned to their submission calendar, enabling the regulatory team to adjust timelines proactively rather than reactively as implementation milestones shifted.
Need a Regulatory Landscape Assessment, Precedent Analysis, or Ongoing Intelligence?
Tell us about your product, your target markets, and which decisions the intelligence needs to support, and we will outline how we can help.
Speak with an ExpertFrequently Asked Questions (FAQ)
What is regulatory intelligence and how does it differ from regulatory strategy?
Regulatory intelligence is the structured process of monitoring, analysing, and interpreting regulatory developments, authority decisions, and precedent. Strategy uses that intelligence to define the regulatory pathway and plan submissions. We do both, but this page covers the intelligence layer: the evidence base, foresight, and analysis that strategy depends on.
How do you source and validate regulatory intelligence?
We monitor primary sources: EMA, MHRA, CMDh, FDA, and EU national competent authorities. We supplement this with public assessment reports, guidance consultations, inspection outcomes, clinical trial registries, and our own project experience across active submissions. All intelligence is reviewed by senior regulatory professionals with therapeutic and procedural expertise before it reaches a client deliverable.
Can you provide intelligence tailored to a specific product or indication?
Yes. Product-specific RI is tailored to your development stage, therapeutic area, and target jurisdictions. It includes analysis of relevant guidance, comparable product approvals and refusals, regulatory precedent, submission timing considerations, and risk-impact scenarios specific to your programme.
What types of deliverables can we expect?
Structured outputs include regulatory landscape reports, annotated trackers, competitor precedent summaries, product-specific briefing notes, and strategy input documents. Deliverables are shaped by the decision they need to support, whether that is scientific advice preparation, dossier planning, board-level reporting, or cross-functional programme alignment.
How is intelligence integrated into project work rather than siloed?
RI is embedded across our regulatory services. It informs scientific advice preparation, dossier strategy, variation planning, due diligence assessments, and lifecycle management. The people doing the intelligence work are the same people running the submissions, which means the analysis reflects what actually matters at each decision point.
How often is intelligence updated?
For ongoing engagements, updates follow a fixed schedule (typically monthly) or align to project milestones. For one-time deliverables, intelligence reflects the most current regulatory positions at delivery. Background horizon scanning continues regardless, so emerging developments are flagged between scheduled reports when they require attention.
Can you support regulatory intelligence beyond the EU, UK, and Switzerland?
Yes. Through regulanet®, we access regulatory intelligence in 90+ countries. This includes local regulatory pathways, procedural nuances, classification rules, and country-specific requirements that may not be publicly available or fully harmonised with international standards.